基于电子病历的癌症幸存者心力衰竭预测评分的发展

Cheng Hwee Soh PhD , Lena Nguyen MSc , Anna Chu MHSc , Agus Salim PhD , Husam Abdel-Qadir MD, PhD , Thomas H. Marwick MBBS, PhD, MPH
{"title":"基于电子病历的癌症幸存者心力衰竭预测评分的发展","authors":"Cheng Hwee Soh PhD ,&nbsp;Lena Nguyen MSc ,&nbsp;Anna Chu MHSc ,&nbsp;Agus Salim PhD ,&nbsp;Husam Abdel-Qadir MD, PhD ,&nbsp;Thomas H. Marwick MBBS, PhD, MPH","doi":"10.1016/j.jacadv.2025.102129","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Awareness of heart failure (HF) as a long-term complication of cancer has led to an interest in HF surveillance among survivors. However, existing HF risk scores are not tailored for survivors and not designed for the use in electronic medical records (EMRs) or administrative data sets where clinical data such as blood pressure and pathology results are often unavailable.</div></div><div><h3>Objectives</h3><div>The objective of the study is to develop a cancer-specific incident HF risk score suitable for screening in EMR or administrative data sets.</div></div><div><h3>Methods</h3><div>The cancer-specific HF prediction from EMRs in survivor health care (CHERISH) risk score was developed from risk variables identified in 16,191 cancer survivors (mean 61 years; 59.5% female) derived from the UK Biobank. External validation was conducted in a population-based Ontario cohort (n = 446,096; mean 67 years; 53.9% female). HF risk classification with CHERISH was compared against the ARIC (Atherosclerotic Risk In Community)-HF score using area under the curve (AUC).</div></div><div><h3>Results</h3><div>The CHERISH score incorporates 11 clinical variables—age, years since cancer diagnosis, coronary heart disease, arrhythmia, myocardial infarct, diabetes, hypertension, leukemia, non-Hodgkin lymphoma, lung cancer, and breast cancer. CHERISH demonstrated strong prediction of 10-year HF incidence during internal validation (AUC: 0.829), exceeding ARIC-HF (AUC: 0.697; <em>P</em> &lt; 0.001). In external validation, CHERISH showed an AUC of 0.721 in predicting 10-year HF incidence, compared to an AUC of 0.751 (<em>P</em> &lt; 0.001) with ARIC-HF.</div></div><div><h3>Conclusions</h3><div>The integration of the CHERISH score into EMR systems may provide large-scale, automated HF risk assessment in cancer survivors, using routinely collected clinical data.</div></div>","PeriodicalId":73527,"journal":{"name":"JACC advances","volume":"4 10","pages":"Article 102129"},"PeriodicalIF":0.0000,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Development of an Electronic Medical Record–Based Score for Heart Failure Prediction in Cancer Survivors\",\"authors\":\"Cheng Hwee Soh PhD ,&nbsp;Lena Nguyen MSc ,&nbsp;Anna Chu MHSc ,&nbsp;Agus Salim PhD ,&nbsp;Husam Abdel-Qadir MD, PhD ,&nbsp;Thomas H. Marwick MBBS, PhD, MPH\",\"doi\":\"10.1016/j.jacadv.2025.102129\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Awareness of heart failure (HF) as a long-term complication of cancer has led to an interest in HF surveillance among survivors. However, existing HF risk scores are not tailored for survivors and not designed for the use in electronic medical records (EMRs) or administrative data sets where clinical data such as blood pressure and pathology results are often unavailable.</div></div><div><h3>Objectives</h3><div>The objective of the study is to develop a cancer-specific incident HF risk score suitable for screening in EMR or administrative data sets.</div></div><div><h3>Methods</h3><div>The cancer-specific HF prediction from EMRs in survivor health care (CHERISH) risk score was developed from risk variables identified in 16,191 cancer survivors (mean 61 years; 59.5% female) derived from the UK Biobank. External validation was conducted in a population-based Ontario cohort (n = 446,096; mean 67 years; 53.9% female). HF risk classification with CHERISH was compared against the ARIC (Atherosclerotic Risk In Community)-HF score using area under the curve (AUC).</div></div><div><h3>Results</h3><div>The CHERISH score incorporates 11 clinical variables—age, years since cancer diagnosis, coronary heart disease, arrhythmia, myocardial infarct, diabetes, hypertension, leukemia, non-Hodgkin lymphoma, lung cancer, and breast cancer. CHERISH demonstrated strong prediction of 10-year HF incidence during internal validation (AUC: 0.829), exceeding ARIC-HF (AUC: 0.697; <em>P</em> &lt; 0.001). In external validation, CHERISH showed an AUC of 0.721 in predicting 10-year HF incidence, compared to an AUC of 0.751 (<em>P</em> &lt; 0.001) with ARIC-HF.</div></div><div><h3>Conclusions</h3><div>The integration of the CHERISH score into EMR systems may provide large-scale, automated HF risk assessment in cancer survivors, using routinely collected clinical data.</div></div>\",\"PeriodicalId\":73527,\"journal\":{\"name\":\"JACC advances\",\"volume\":\"4 10\",\"pages\":\"Article 102129\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-09-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JACC advances\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2772963X2500554X\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JACC advances","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772963X2500554X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

心衰(HF)作为癌症的一种长期并发症的认识引起了对幸存者心衰监测的兴趣。然而,现有的心衰风险评分并不是为幸存者量身定制的,也不是为电子病历(emr)或管理数据集设计的,因为这些数据通常无法获得血压和病理结果等临床数据。该研究的目的是开发一种适用于EMR或管理数据集筛查的癌症特异性事件HF风险评分。方法根据来自英国生物银行(UK Biobank)的16191名癌症幸存者(平均61岁,59.5%为女性)的风险变量,通过emr对幸存者医疗保健(珍惜)风险评分进行癌症特异性心衰预测。外部验证在以人群为基础的安大略省队列中进行(n = 446,096,平均67岁,53.9%为女性)。使用曲线下面积(AUC)将用珍惜评分的HF风险分类与ARIC(社区动脉粥样硬化风险)-HF评分进行比较。结果该评分包括年龄、癌症诊断年限、冠心病、心律失常、心肌梗死、糖尿病、高血压、白血病、非霍奇金淋巴瘤、肺癌、乳腺癌等11个临床变量。在内部验证中,珍爱显示出较强的10年HF发病率预测(AUC: 0.829),超过ARIC-HF (AUC: 0.697; P < 0.001)。在外部验证中,珍爱预测10年HF发病率的AUC为0.721,而ARIC-HF的AUC为0.751 (P < 0.001)。将珍爱评分整合到EMR系统中,可以使用常规收集的临床数据,为癌症幸存者提供大规模、自动化的心衰风险评估。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Development of an Electronic Medical Record–Based Score for Heart Failure Prediction in Cancer Survivors

Background

Awareness of heart failure (HF) as a long-term complication of cancer has led to an interest in HF surveillance among survivors. However, existing HF risk scores are not tailored for survivors and not designed for the use in electronic medical records (EMRs) or administrative data sets where clinical data such as blood pressure and pathology results are often unavailable.

Objectives

The objective of the study is to develop a cancer-specific incident HF risk score suitable for screening in EMR or administrative data sets.

Methods

The cancer-specific HF prediction from EMRs in survivor health care (CHERISH) risk score was developed from risk variables identified in 16,191 cancer survivors (mean 61 years; 59.5% female) derived from the UK Biobank. External validation was conducted in a population-based Ontario cohort (n = 446,096; mean 67 years; 53.9% female). HF risk classification with CHERISH was compared against the ARIC (Atherosclerotic Risk In Community)-HF score using area under the curve (AUC).

Results

The CHERISH score incorporates 11 clinical variables—age, years since cancer diagnosis, coronary heart disease, arrhythmia, myocardial infarct, diabetes, hypertension, leukemia, non-Hodgkin lymphoma, lung cancer, and breast cancer. CHERISH demonstrated strong prediction of 10-year HF incidence during internal validation (AUC: 0.829), exceeding ARIC-HF (AUC: 0.697; P < 0.001). In external validation, CHERISH showed an AUC of 0.721 in predicting 10-year HF incidence, compared to an AUC of 0.751 (P < 0.001) with ARIC-HF.

Conclusions

The integration of the CHERISH score into EMR systems may provide large-scale, automated HF risk assessment in cancer survivors, using routinely collected clinical data.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
JACC advances
JACC advances Cardiology and Cardiovascular Medicine
CiteScore
1.90
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信